The Pharmacy Blinked, The Chip King Flexed, And Cars Got Smarter

One healthcare giant just made a political trade that could ripple through the whole drug aisle. The chip bellwether just dropped a big quarter, but the real tell is what it says next. And a major automaker quietly picked the brains behind its future car screens. We will lay out the clean setups, where to wait, and what would make these moves stick.

Easier monetary policy is changing market conditions.

Liquidity is improving across risk assets, including crypto.

Institutional investors are increasing exposure quietly.

Regulatory momentum is turning more favorable under a pro-crypto administration.

Download it now plus $788 in instant bonuses—including our #1 crypto pick for this market.

Get instant access to everything now.

© 2026 Boardwalk Flock LLC. All Rights Reserved.

2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States

*The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies.

*Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

Futures are basically flat as traders wait on the jobs report like it’s a season finale. The other wildcard is a possible Supreme Court tariff ruling, which could wake up the whole market in a hurry.

Tech just took a small breather, the Dow’s been steadier, and the feeling is don’t do anything dumb until the data hits.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings:

Economic Reports:

Fed Speakers:

TSMC (NYSE: TSM) posted a strong fourth-quarter revenue jump, beating forecasts as AI demand keeps the fabs humming. This is the cleanest kind of bullish headline: more orders, more output, fewer excuses.

Still, this stock rarely moves on the past. The real party is next week, when guidance and capex plans hit. That is where the market decides if this was a great quarter or the start of another leg higher. If management signals steady pricing power and strong demand into 2026, the dip buyers usually come back fast. If the outlook sounds cautious, the stock can sag even after good numbers.

So treat this like a great trailer, not the whole movie. The setup is solid, but the next scene matters more than the last one.

My Take For You: If you are not in, start small, only on a pullback, and add after the guidance confirms momentum. If you are in, hold, but keep some dry powder for post-earnings volatility.

My Verdict: High-quality leader, but the next catalyst is guidance, not the headline.

Qualcomm (NASDAQ: QCOM) landed a long-term infotainment role for Volkswagen’s new software platform, starting in 2027. In plain English, Qualcomm is getting invited to sit behind the steering wheel screen where the buttons, maps, and apps live. That is a sticky spot once you are in it.

This is not the kind of news that doubles a stock overnight, but it is the kind that quietly upgrades the story. Cars are turning into rolling computers, and whoever supplies the brains gets a longer runway than whoever sells the pretty trim.

The big watch item is follow-through: does this expand to more models, and does it pull in other automakers who hate being left behind.

For traders, the danger is getting excited about a 2027 payoff and overpaying in 2026. For investors, the appeal is simple: more design wins, less single-cycle drama.

My Take For You: If you want exposure, consider a starter position on a red day and add only if more auto wins stack up. If you own it, let it ride, but trim a bit on sharp pops.

My Verdict: Solid long-game win, best played patiently, not chased.

Economic confidence weakens when debt rises, wars expand, and currencies lose trust.

Many investors stay frozen while purchasing power quietly slips away.

History favors those who move early when political shifts change the landscape.

This Patriot’s Tax Shield outlines how tangible gold can serve as a defensive asset in uncertain times.

A free Wealth Protection Guide explains why Trump’s return could reshape demand for gold.

Click here to download the FREE Wealth Protection Guide now.

Johnson and Johnson (NYSE: JNJ) just struck a deal to cut drug prices in the U.S., and in return it gets tariff exemptions. That is the corporate version of handing over a little margin today so you can stop sweating a much bigger bill tomorrow.

The market will probably like the clarity even if the details are still fuzzy. Lower prices can sting, but tariffs can sting in a way that shows up everywhere at once. Plus, the company is pairing this with more U.S. manufacturing plans, which tends to play well in the current political climate.

The key is not cheering the headline; it is watching the fine print. Which drugs, how deep are the discounts, and does the tariff relief meaningfully offset the give. Until those answers land, this feels like a steady-name story with a fresh catalyst, not a rocket ship.

My Take For You: If you own it, hold, but consider trimming a little into strength. If you do not, wait for details and look for a calmer entry after the first round of hot takes.

My Verdict: Defensive core candidate, but let the paperwork catch up to the headline.

Biotech rumor season is cooking again. A report says Merck is talking numbers, and the stock is acting like it just found a golden ticket in the couch cushions.

The catch is that talks are not a deal, and last week proved how fast a denial can slap the price back down.

Rates eased, a bank bumped the target, and Rocket is getting that fresh-cut grass optimism. Traders are basically buying the idea that 2026 mortgages get less painful.

Problem is, mortgage apps just dipped, so the vibes are ahead of the proof.

Analyst cheers, stock snoozes. The target went up, but shares are sliding anyway, which usually means profit-taking or rotation, not a disaster.

This name moves like a commuter train, not a rocket, so red mornings can be entry gifts if the track stays intact.

History shows every dominant empire follows the same path: debt, debasement, and decline.

The warning signs are no longer subtle—runaway deficits, weakening currency power, and global institutions quietly repositioning.

Markets are already responding, with hard assets outperforming traditional benchmarks and central banks accelerating their moves.

This is not a forecast. It is a pattern repeating in real time.

There is still a narrow window to reposition retirement assets into stores of value that have survived every monetary collapse in history.

Miss the shift, and the cost is paid later.

See How the Shift Works

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.